EAC 2022 Update in Allergy, Asthma and Immunology
The EAC 2022 Update in Allergy, Asthma & Immunology meeting will provide learners with knowledge regarding novel disease state developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology. Learners will not only gain insights with regard to selecting the best therapeutic alternative for each patient, but they will also have the opportunity to develop novel strategies designed to enhance therapeutic adherence through shared decision making. The format will incorporate problem based learning, uniquely designed to interface with lectures in context to the core issues relevant to the cases.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and Eastern Allergy Conference (EAC). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 14 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity
CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 14 contact hours.
Commercial Support
This activity is supported in part by independent medical education grants from Stallergenes Greer, CSL Behring and BioCryst.
Target Audience
Practicing allergists
Allied health professionals
Learning Objectives
Upon completion of this activity the participant should be able to:
At the conclusion of this activity, participants should be able to:
• Describe signaling pathways and their clinical implications in atopic dermatitis
• Outline an endotype, phenotype and guideline-based approach to the treatment of asthma
• Discuss strategies to overcome COVID-19 vaccine misinformation and hesitancy
• Diagnose and manage eosinophilic gastrointestinal disorders
• Diagnose and manage non IgE-mediated drug allergy
• Diagnose and manage hereditary angioedema
• Diagnose and manage chronic urticaria
• Discuss current and future allergy immunotherapy treatment options for respiratory
allergies
• Outline an approach to the use of biologics for allergic diseases, including asthma, chronic
urticaria and atopic dermatitis
• Evaluate for potential immunodeficiency
• Discuss the “long COVID-19 syndrome”
Michael Blaiss, MD – Speaker
Advisory Board – ALK, AstraZeneca, Merck, Regeneron
Research Grant – Merck
Consultant- ALK, Sanofi Genzyme, Covis, Perrigo, TerSera Pharma, Lanier Biopharmaceuticals
Speaker- Merck, Regeneron, Sanofi Genzyme
Don Bukstein, MD – Speaker
Speaker – AstraZeneca, Teva, Regeneron
Paula Busse, MD – Speaker
Speaker – BioCryst
Advisor – CSL Behring, CVS, Takeda, Regeneron, Novartis
Mark Corbett, MD – Speaker
Speaker – Sanofi Regeneron, OptiNose
Advisor – AstraZeneca, ALK, Takeda
William Corrao, MD – Planner, Moderator
Speaker – Boehringer Ingelheim, GSK
Ray Davis, MD – Speaker
Advisor – Shire, Bayalta, Circassia, Takeda, Genentech, Novartis, ALK, DBV Technologies, Regeneron, Sanofi, TEVA
Hal Hoffman, MD – Speaker
Speaker –Novartis
Independent Contractor– Novartis, Kiniksa, Aclaris, Takeda, Zomagen
Shyam Joshi, MD – Speaker
Advisor – Sanofi, BioCryst, Takeda, Leo Pharma
Andrew Liu, MD – Speaker
Research Grant – Avillion, ResMed/Propeller Health, Phadia/ThermoFisher
Advisor – Avillion, ResMed/Propeller Health, Phadia/ThermoFisher, Labcorp
Harold Nelson, MD – Speaker
Speaker – ALK
Princess Ogbogu, MD – Speaker
Research Grant – AstraZeneca, GSK
Advisor – AstraZeneca, GSK
Jordan Orange, MD – Speaker
Speaker – SOBI
Advisor – CSL Behring, Grifols, Editas, EdiTy, TEVA, Takeda, Johnson & Johnson
Robert Settipane, MD – Planner/Moderator
Independent Contractor - AstraZeneca, BioCryst, GSK, Regeneron, Teva
Russell Settipane, MD – Planner/Moderator/Speaker/Reviewer
Speaker – AbbVie, Amgen, AstraZeneca, BioCryst, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Grifols, Pharming, Pfizer, Regeneron, Sanofi, Takeda
Advisory Board – AbbVie, Aimmune, AstraZeneca, BioCryst, Boehringer Ingelheim, DBV Technologies, GlaxoSmithKline, Kalvista, Pharming, Pfizer
Independent Contractor – AstraZeneca, GlaxoSmithKline, TEVA, BioCryst, Regeneron
Dana Wallace, MD – Speaker
Speaker – Sanofi
Advisory Board – Bryn, Sanofi
The following have no relevant financial relationships to disclose:
Joseph Bellanti, MD – Planner/Speaker
William Greisner, III, MD – Planner/Moderator
Ginny Loiselle – Coordinator
Katelyn Loiselle, BSN, RN – Planner
Michael Slaughter, MD – Planner/Moderator
Kelli Wilson – Planner
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Eastern Allergy Conference (EAC). The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 14 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 14.00 AMA PRA Category 1 Credit™
- 14.00 Attendance
- 14.00 CBRN